MannKind Corporation

NASDAQ:MNKD

Biotechnology

Healthcare
$4.07 -0.51%

-$0.02 today

Market cap
$1.31B
Beta
1.11
P/E (TTM)
-50.3
EPS (TTM)
-$0.08
52W Low $2.23High $6.51

Volume 2.12M

Average 5.73M

MNKD Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

MannKind CorporationNASDAQ: MNKD

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit grows, but more slowly than its trailing trend

Q1 FY2026 gross profit of $68.33M rose 12.3% year over year, behind the +23.4% change in trailing-twelve-month gross profit. Sequentially, it fell 22.2% from the prior quarter. Over 3 fiscal years it compounded at +89.5% a year.

Context

  • Gross profit amounted to 82.5% of revenue in FY2025, up 9.3 pp from a year earlier.
  • Gross profit increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +12.3% toward the trailing-twelve-month pace of +23.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$68.33M-22.2% QoQ
Last fiscal yearDec 2025
$287.81M+37.8% YoY
LTMMar 2026
$274.05M+23.4% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+12.3%——
1 year+37.8%——
3-year CAGR+89.5%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
287.81M USD
Year-over-year change
+37.8%
4-year CAGR
+67.5%

Gross Profit vs competitors

How MNKD compares with its peers on the latest reported figures

  • MNKD's LTM Mar 2026 gross profit of $274.05M is the highest of the 6 companies compared; the peer median is $76.32M.
  • Its year-over-year change of +23.4% is the 4th highest of 6, against a peer median of +42.5%.
  • Gross profit amounts to 76.0% of revenue for MNKD, versus a peer median of 78.7%.
MNKD Competitors Peer median
Gross Profit for MNKD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MNKDMannKind CorporationLTM Mar 2026$274.05M +23.4%+89.5%76.0%
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$256.89M +42.5%+39.6%81.6%
TBPHTheravance Biopharma, Inc.LTM Mar 2026$88.23M +251.0%—80.4%
SPRYARS Pharmaceuticals, Inc.LTM Mar 2026$76.32M -7.1%—77.1%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$851K +21375.0%—37.1%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026-$121K +2.4%-83.1%—
AVLNAvalyn Pharma Inc. Common Stock—— ———
Peer median (excluding MNKD) $76.32M+42.5%-21.8%78.7%

Competitors are the stored peer set for MNKD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue75.44M99.77M198.96M285.5M348.97M
Cost of Revenue38.86M57.5M62.77M76.6M61.16M
Gross Profit36.59M42.27M136.19M208.9M287.81M
Gross Margin48.5%42.4%68.5%73.2%82.5%
Research & Development12.31M19.72M31.28M45.89M66.35M
Selling, General & Admin77.42M91.47M94.31M94.33M144.14M
Operating Expenses83.61M106.38M127.51M136.32M249.01M
Depreciation & Amortization3.24M6.31M4.54M8.97M12.28M
EBITDA(61.11M)(56.32M)15.13M77.47M27.52M
EBITDA Margin-81.0%-56.4%7.6%27.1%7.9%
Operating Income(47.02M)(64.11M)8.68M72.59M38.8M
Operating Margin-62.3%-64.3%4.4%25.4%11.1%
Interest Income112K2.51M6.15M12.62M0
Interest Expense16.58M24.77M25.16M37.98M13.83M
Other Income / Expenses(33.9M)(23.29M)(19.06M)(42.07M)(37.39M)
Income Before Tax(80.93M)(87.4M)(10.38M)30.52M1.41M
Pre-Tax Margin-107.3%-87.6%-5.2%10.7%0.4%
Income Tax Expense001.56M2.93M(4.46M)
Net Income(80.93M)(87.4M)(11.94M)27.59M5.86M
Net Margin-107.3%-87.6%-6.0%9.7%1.7%
EPS (Basic)(0.37)(0.44)(0.04)0.100.02
EPS (Diluted)(0.37)(0.44)(0.04)0.100.02
Weighted Avg Shares249.24M257.09M267.01M274.42M305.64M
Weighted Avg Shares (Diluted)249.24M257.09M267.01M283.84M314.11M

MannKind Corporation

NASDAQ:MNKD

Intrinsic Alpha fair value

Locked

Current Price

$4.07

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.